Yoshihiro Hatta

3.5k total citations
159 papers, 2.3k citations indexed

About

Yoshihiro Hatta is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Yoshihiro Hatta has authored 159 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hematology, 38 papers in Molecular Biology and 38 papers in Genetics. Recurrent topics in Yoshihiro Hatta's work include Chronic Myeloid Leukemia Treatments (38 papers), Acute Myeloid Leukemia Research (29 papers) and Acute Lymphoblastic Leukemia research (27 papers). Yoshihiro Hatta is often cited by papers focused on Chronic Myeloid Leukemia Treatments (38 papers), Acute Myeloid Leukemia Research (29 papers) and Acute Lymphoblastic Leukemia research (27 papers). Yoshihiro Hatta collaborates with scholars based in Japan, United States and Norway. Yoshihiro Hatta's co-authors include HP Koeffler, Noriyoshi Iriyama, Masao Tomonaga, Seisho Takeuchi, Jin Takeuchi, Carl W. Miller, Roberta Morosetti, Toshiyasu Hirama, Norihiko Kawamata and Yohei Yamada and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yoshihiro Hatta

147 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yoshihiro Hatta Japan	23	848	828	654	456	414	159	2.3k
Miller Cw United States	28	1.2k 1.4×	1.3k 1.6×	295 0.5×	497 1.1×	298 0.7×	59	2.5k
N Kamada Japan	32	475 0.6×	1.7k 2.1×	1.3k 2.0×	668 1.5×	344 0.8×	149	4.0k
Nobuyoshi Arima Japan	23	421 0.5×	428 0.5×	409 0.6×	979 2.1×	157 0.4×	88	1.9k
Junichi Kameoka Japan	22	1.3k 1.5×	730 0.9×	285 0.4×	722 1.6×	469 1.1×	88	2.4k
Masaaki Higashihara Japan	25	477 0.6×	675 0.8×	412 0.6×	542 1.2×	618 1.5×	127	2.1k
Toshiyasu Hirama Japan	19	535 0.6×	665 0.8×	589 0.9×	295 0.6×	154 0.4×	47	1.9k
Taizo Tasaka Japan	23	936 1.1×	724 0.9×	512 0.8×	155 0.3×	496 1.2×	91	2.0k
David Joske Australia	20	634 0.7×	741 0.9×	906 1.4×	400 0.9×	774 1.9×	45	2.6k
Gandhi Damaj France	28	514 0.6×	329 0.4×	501 0.8×	830 1.8×	841 2.0×	125	2.3k
Hideaki Mizoguchi Japan	36	672 0.8×	911 1.1×	1.5k 2.4×	941 2.1×	405 1.0×	141	3.5k

Countries citing papers authored by Yoshihiro Hatta

Since Specialization

Citations

This map shows the geographic impact of Yoshihiro Hatta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihiro Hatta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihiro Hatta more than expected).

Fields of papers citing papers by Yoshihiro Hatta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshihiro Hatta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihiro Hatta. The network helps show where Yoshihiro Hatta may publish in the future.

Co-authorship network of co-authors of Yoshihiro Hatta

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshihiro Hatta. A scholar is included among the top collaborators of Yoshihiro Hatta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshihiro Hatta. Yoshihiro Hatta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Takaku, Tomoiku, Naoki Watanabe, Noriyoshi Iriyama, et al.. (2025). Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia. International Journal of Hematology.

Hatta, Yoshihiro, Koji Izutsu, Makoto Onizuka, et al.. (2024). JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL. International Journal of Hematology. 120(4). 394–413. 1 indexed citations

Hayakawa, Fumihiko, Naoki Mori, Kiyotoshi Imai, et al.. (2024). Nelarabine‐combined chemotherapy improves outcome of T‐cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T‐ALL213‐O. Cancer Science. 116(2). 453–461. 1 indexed citations

Toya, Takashi, Masatoshi Sakurai, Jun Kato, et al.. (2023). Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Advances. 8(5). 1084–1093. 4 indexed citations

Tokuhira, Michihide, Yuta Kimura, Takayuki Tabayashi, et al.. (2023). Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. International Journal of Hematology. 118(2). 210–220. 1 indexed citations

Matsumoto, Shuhei, Hiromichi Takahashi, Takashi Hamada, et al.. (2023). [Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma].. PubMed. 64(4). 255–259. 1 indexed citations

Kuwana, Masataka, Tomoki� Ito, Shugo Kowata, et al.. (2022). Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study. British Journal of Haematology. 200(6). 802–811. 9 indexed citations

Iriyama, Noriyoshi, Katsuhiro Miura, Y. Uchino, et al.. (2021). Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia. Chemotherapy. 67(2). 96–101. 2 indexed citations

Hamada, Takashi, Noriyoshi Iriyama, Hiromichi Takahashi, et al.. (2018). Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia. Clinical Drug Investigation. 38(9). 813–818. 1 indexed citations

10.

Nakagawa, Masaru, Shigeyuki Uno, Noriyoshi Iriyama, et al.. (2018). Combined treatment with benzo[a]pyrene and 1α,25-dihydroxyvitamin D3 induces expression of plasminogen activator inhibitor 1 in monocyte/macrophage-derived cells. Toxicology and Applied Pharmacology. 345. 48–56. 2 indexed citations

11.

Uno, Shigeyuki, Torahiko Tanaka, Makoto Fujimaki, et al.. (2018). Sensitive typing of reverse ABO blood groups with a waveguide-mode sensor. Journal of Bioscience and Bioengineering. 126(1). 131–137. 4 indexed citations

12.

Iriyama, Noriyoshi, Michihide Tokuhira, Tomoiku Takaku, et al.. (2017). Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leukemia Research. 54. 55–58. 13 indexed citations

13.

Iriyama, Noriyoshi, Hirotsugu Hino, Shota Moriya, et al.. (2016). Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy. Blood. 128(22). 4478–4478. 1 indexed citations

14.

Hatta, Yoshihiro, Y. Uchino, Hiromichi Takahashi, et al.. (2011). Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Experimental and Therapeutic Medicine. 3(2). 304–308. 6 indexed citations

15.

Mizuta, Shuichi, Masamitsu Yanada, Isamu Sugiura, et al.. (2008). Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood. 112(11). 462–462. 1 indexed citations

16.

Hatta, Yoshihiro, et al.. (2005). Pure Red Cell Aplasia and Myelofibrosis in B-cell Neoplasm. Journal of International Medical Research. 33(4). 460–466. 6 indexed citations

17.

Hatta, Yoshihiro, Megumi Tanaka, Yoshitaka Kaneita, et al.. (2003). Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.. PubMed. 22(3). 631–7. 5 indexed citations

18.

Hatta, Yoshihiro, Konstantin S. Spirin, Taizo Tasaka, et al.. (1997). Analysis of p18^INK4C in adult T‐cell leukaemia and non‐Hodgkin's lymphoma. British Journal of Haematology. 99(3). 668–670. 19 indexed citations

19.

Koike, Michiaki, Seisho Takeuchi, Jun Yokota, et al.. (1997). Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer. Genes Chromosomes and Cancer. 19(1). 1–5. 55 indexed citations

20.

Shiohara, Masaaki, Konstantin S. Spirin, Said Jw, et al.. (1996). Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies.. PubMed. 10(12). 1897–900. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact